Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …

Tuberculosis (TB) in humans is characterized by formation of immune-rich granulomas in
infected tissues, the architecture and composition of which are thought to affect disease …

Despite having been identified as the organism that causes tuberculosis in 1882,
Mycobacterium tuberculosis has managed to still evade our understanding of the protective …

The pathophysiology of adverse events following programmed cell death protein 1 (PD-1)
blockade, including tuberculosis (TB) and autoimmunity, remains poorly characterized. We …

Pulmonary granulomas are widely considered the epicenters of the immune response to
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). Recent animal …

Importance Anti− PD-1 (anti− programmed cell death 1) and anti− PD-L1 (anti− programmed
cell death ligand 1) regimens are preferred therapies for many cancers, including cancers …

Boosting immune cell function by targeting the coinhibitory receptor PD-1 may have
applications in the treatment of chronic infections. Here, we examine the role of PD-1 during …

Vaccine development against tuberculosis (TB) is based on the induction of adaptive
immune responses endowed with long-term memory against mycobacterial antigens …

Greater understanding of tumour immunobiology has led to a new era of cancer treatment in
which immuno-oncology (IO) therapies are used to boost anti-cancer immune responses …